Trifluoperazine (Stelazine): the high-potency phenothiazine

Trifluoperazine — sold historically as Stelazine and now mostly as a generic — was first approved by the FDA in 1959. It belongs to the phenothiazine class chemically but, like fluphenazine, is a high-potency drug pharmacologically. For decades it was a routine option for schizophrenia and is still used in many countries, particularly in lower-resource health systems where its low cost and wide availability matter.

How trifluoperazine works

Trifluoperazine is primarily a dopamine D2 receptor blocker. Like other high-potency drugs, it has limited activity at histamine, muscarinic, and adrenergic receptors — which means less sedation, less weight gain, and less orthostatic hypotension than low-potency phenothiazines. The trade-off is more EPS at therapeutic doses.

What it treats

FDA-approved indications include:

• Schizophrenia
• Generalised non-psychotic anxiety at lower doses (a narrow indication, used cautiously)

Today the anxiety indication is rarely used because safer first-line options exist (SSRIs, buspirone, short-term benzodiazepines). The medication's modern role is essentially in schizophrenia.

Forms and dosing

Trifluoperazine is available only as oral tablets in the US (oral concentrate is occasionally available). There is no commercially available depot form. Dosing for schizophrenia is individualised and decided with your prescriber.

How effective it is

Across head-to-head trials and meta-analyses, high-potency typicals like trifluoperazine, fluphenazine, and haloperidol show comparable efficacy on positive symptoms. The most influential network meta-analysis on antipsychotic efficacy is Leucht et al. in The Lancet in 2013, which found typical antipsychotics broadly effective, with somewhat higher EPS than most atypicals.

Side effects

Movement

Like other high-potency typicals, trifluoperazine has a meaningful EPS profile:

• Acute dystonia in the first days
• Parkinsonism (tremor, rigidity, shuffling gait)
• Akathisia (internal restlessness)
• Tardive dyskinesia with chronic exposure (see our guide)

Anticholinergic medications (benztropine, trihexyphenidyl) are sometimes added to reduce acute EPS, though they have their own side effects.

Other

• Sedation (less than chlorpromazine, but real)
• Hyperprolactinaemia
• Photosensitivity
• QT prolongation
• Orthostatic hypotension (mild to moderate)
• Modest weight gain (less than most atypicals)

Where trifluoperazine fits today

• Patients who have responded well to it historically
• Settings where atypicals are unavailable or unaffordable
• Patients in whom newer drugs have failed and a different D2 blocker is being tried

Where it usually doesn't fit

• First-episode patients in well-resourced settings
• People with prior severe EPS or tardive dyskinesia
• Older adults with dementia (FDA boxed warning across the antipsychotic class)
• People with significant cardiac conduction problems

Practical points

• Wear sunscreen and protective clothing outdoors
• Be honest with your prescriber about restlessness — akathisia is easily missed and very treatable
• Ask how often EPS will be screened (the AIMS scale is the standard tool)
• Don't stop suddenly — taper with prescriber guidance

Bottom line

Trifluoperazine is a quietly competent older antipsychotic that has been overshadowed in marketing terms but remains a valid clinical choice. As with any antipsychotic, the right answer is the one that gets a particular person to stability with the fewest side effects they personally find intolerable — and that conversation belongs in your prescriber's office, not in marketing copy.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.